

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page

1

of 2

**Complete if Known**

Application Number	09/606,433
Filing Date	June 28, 2000
First Named Inventor	McGee, Lawrence R.
Art Unit	1625
Examiner Name	Seaman, J.

Attorney Docket Number 018781-002710US

U.S. PATENT DOCUMENTS					
Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MM	AA	5,202,336	04/13/1993	Mohrs et al.	
	AB	5,250,549	10/05/1993	Yoshino et al.	
	AC	5,780,483	07/14/1998	Widdowson et al.	
	AD	5,990,126	11/23/1999	Park et al.	
	AE	6,294,559 B1	09/25/2001	Smith	
	AF	6,353,011 B1	03/05/2002	Pershadsingh et al.	
	AG	6,369,075 B1	04/09/2002	Ruggeri et al.	
	AH	6,583,157 B2	06/24/2003	McGee et al.	
	AI	2003-0088103 A1	05/08/2003	Houze et al.	
	AJ	USSN 10/278,851	n/a	McGee et al.	
MM	AK	USSN 10/456,932	n/a	Jaen et al.	

RECEIVED

AUG 07 2003

OFFICE OF PETITIONS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
MM	AL	EP	0 306 222	A2	03/08/1989	Hokko Chemical Industry Co., Ltd.	<input type="checkbox"/>
	AM	EP	0 472 053	B1	06/17/1998	Eisai Co., Ltd.	<input type="checkbox"/>
	AN	WO	95/33461	A1	12/14/1995	SmithKline Beecham Corporation	<input type="checkbox"/>
	AO	WO	99/50237	A1	10/07/1999	Hiroyoshi Hidaka	<input type="checkbox"/>
	AP	WO	01/60807	A1	08/23/2001	Merck & Co. Inc.	<input type="checkbox"/>
	AQ	WO	01/70723	A1	09/27/2001	Mitsui Chemicals, Inc.	<input type="checkbox"/>
	AR	WO	01/83427	A1	11/08/2001	Sankyo Company, Limited	<input type="checkbox"/>
	AS	WO	01/87860	A2	11/22/2002	Ortho-McNeil Pharmaceutical, Inc.	<input type="checkbox"/>
	AT	WO	01/87861	A2	11/22/2001	Ortho-McNeil Pharmaceutical, Inc.	<input type="checkbox"/>
	AU	WO	01/87862	A2	11/22/2001	Ortho-McNeil Pharmaceutical, Inc.	<input type="checkbox"/>
MM	AV	WO	01/95906	A1	12/20/2001	SmithKline Beecham P.L.C.	<input type="checkbox"/>

Examiner Signature

JM Seaman

Date Considered

2/4/2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	09/606,433		
		Filing Date	June 28, 2000		
		First Named Inventor	McGee, Lawrence R.		
		Art Unit	1625		
		Examiner Name	Seaman, J.		
Page	2	of	2	Attorney Docket Number	018781-002710US

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>DM</i>	AW	Cain <i>et al.</i> , "Potential antitumor agents. 14. Acridylmethanesulfonanilides," <i>J. Med. Chem.</i> 17(9):922-930 (1974)	
	AX	Chaturvedi <i>et al.</i> , "Antibacterial studies of 7-( $\alpha$ -substituted sulfonamido)methyl- and 7-( $\alpha$ -substituted sulfonamido)phenyl-8-hydroxyquinolines," <i>Journal of the Indian Chemical Society</i> 61(2):175-176 (1984) (Abstract. Chem. Abstract Accession Number: 101:87311).	
	AY	Collins <i>et al.</i> , "N-(2-Benzoylphenyl)-L-tyrosine PPAR $\gamma$ agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," <i>J. Med. Chem.</i> 41(25):5037-5054 (1998)	
	AZ	Dumas <i>et al.</i> , "Synthesis and structure-activity relationships of novel small molecule cathepsin D inhibitors," <i>Bioorg. Med. Chem. Lett.</i> 9(17):2531-2536 (1999) (Abstract. Chem. Abstract Accession Number: 131:336969)	
	BA	Jiang <i>et al.</i> , "PPAR- $\gamma$ agonists inhibit production of monocyte inflammatory cytokines," <i>Nature</i> 391:82-86 (1998)	
	BB	Ricote <i>et al.</i> , "The peroxisome proliferator-activated receptor- $\gamma$ is a negative regulator of macrophage activation," <i>Nature</i> 391:79-82 (1998)	
	BC	Spiegelman, B.M., "PPAR- $\gamma$ : adipogenic regulator and thiazolidinedione receptor," <i>Diabetes</i> 47:507-514 (1998)	
<i>DM</i>	BD	<i>The Merck Index</i> , 10th Ed., Windholz <i>et al.</i> , eds. Merck & Co., Inc., Rahway, NJ., pp. 849-850, Abstract 5792 (1983).	

RECEIVED

AUG 07 2003

OFFICE OF PETITIONS

Examiner Signature	<i>Don Seaman</i>	Date Considered	2/4/2004
--------------------	-------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.  
60011130 v3